Moderna (NASDAQ:MRNA) PT Raised to $150.00 at Cowen

Moderna (NASDAQ:MRNAGet Rating) had its price target lifted by equities researchers at Cowen from $130.00 to $150.00 in a report released on Wednesday, The Fly reports. Cowen’s price objective would suggest a potential downside of 23.76% from the stock’s current price.

A number of other brokerages have also recently weighed in on MRNA. Bank of America increased their target price on shares of Moderna from $160.00 to $182.00 in a report on Tuesday, November 15th. Jefferies Financial Group raised shares of Moderna from a “hold” rating to a “buy” rating and increased their target price for the stock from $170.00 to $275.00 in a report on Monday, December 19th. Cowen dropped their target price on shares of Moderna from $165.00 to $145.00 in a report on Thursday, October 20th. Piper Sandler increased their target price on shares of Moderna from $214.00 to $217.00 and gave the stock an “overweight” rating in a report on Tuesday, December 20th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Moderna from $185.00 to $225.00 in a report on Wednesday, January 11th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Moderate Buy” and a consensus target price of $192.00.

Moderna Trading Down 0.1 %

MRNA opened at $196.76 on Wednesday. The stock has a market capitalization of $75.59 billion, a PE ratio of 7.12 and a beta of 1.71. The firm’s fifty day moving average price is $185.97 and its 200 day moving average price is $161.27. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.10 and a quick ratio of 1.80. Moderna has a 12-month low of $115.03 and a 12-month high of $217.25.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $2.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.04 by ($0.51). The company had revenue of $3.36 billion during the quarter, compared to analyst estimates of $3.33 billion. Moderna had a net margin of 55.00% and a return on equity of 70.03%. As a group, research analysts expect that Moderna will post 21.31 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $147.10, for a total value of $5,884,000.00. Following the completion of the transaction, the chief executive officer now owns 5,411,946 shares in the company, valued at approximately $796,097,256.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $200.20, for a total value of $2,002,000.00. Following the completion of the transaction, the director now owns 2,247,209 shares in the company, valued at approximately $449,891,241.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $147.10, for a total transaction of $5,884,000.00. Following the completion of the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at approximately $796,097,256.60. The disclosure for this sale can be found here. Insiders sold 445,899 shares of company stock worth $80,212,386 in the last 90 days. Corporate insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Moderna

Large investors have recently made changes to their positions in the business. Total Clarity Wealth Management Inc. bought a new position in shares of Moderna during the 2nd quarter valued at about $25,000. FinTrust Capital Advisors LLC lifted its stake in Moderna by 754.5% during the second quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock valued at $31,000 after buying an additional 166 shares in the last quarter. Armstrong Advisory Group Inc. purchased a new stake in Moderna during the fourth quarter valued at about $38,000. Ronald Blue Trust Inc. lifted its stake in Moderna by 307.4% during the fourth quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock valued at $26,000 after buying an additional 166 shares in the last quarter. Finally, EWG Elevate Inc. purchased a new stake in Moderna during the fourth quarter valued at about $41,000. Institutional investors own 63.11% of the company’s stock.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

The Fly logo

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.